Lannett Company Inc (LCI.N)
16.60USD
20 Apr 2018
$-0.05 (-0.30%)
$16.65
$16.70
$17.30
$16.55
101,052
117,866
$30.35
$14.48
Wed, Feb 14 2018
BRIEF-Lannett Company Files For Potential Mixed Shelf Offering
* LANNETT COMPANY INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2GblSC4) Further company coverage:
BRIEF-Lannett Co Reports Q2 Earnings Per Share $0.37
* LANNETT ANNOUNCES FISCAL 2018 SECOND-QUARTER FINANCIAL RESULTS; REPORTS RECORD REVENUES, STRONG EARNINGS
BRIEF-Lannett Co Voluntarily Pays Down $25 Mln Of Term Loans
* LANNETT COMPANY SAYS $25 MILLION PAY DOWN OF TERM LOANS WILL SAVE CO ABOUT $1.7 MILLION IN ANNUALIZED CASH INTEREST EXPENSE, AT CURRENT RATES Source text for Eikon: Further company coverage:
BRIEF-Lannett Enters Into Consulting Agreement With Former CEO, Bedrosian
* LANNETT ENTERS INTO CONSULTING AGREEMENT WITH FORMER CEO, ARTHUR BEDROSIAN
BRIEF-Lannett Names Timothy Crew To Board Of Directors
* LANNETT COMPANY INC - WITH CREW'S APPOINTMENT, TOTAL NUMBER OF DIRECTORS IS SEVEN Source text for Eikon: Further company coverage:
BRIEF-Lannett Appoints Timothy Crew As CEO
* LANNETT COMPANY INC - TIMOTHY CREW WILL SUCCEED ARTHUR BEDROSIAN, WHO WILL CONTINUE TO SERVE AS CEO UNTIL CREW JOINS COMPANY
BRIEF-Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution
* LANNETT ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR COCAINE HYDROCHLORIDE TOPICAL SOLUTION, A PROPRIETARY ANESTHETIC PRODUCT
BRIEF-Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL
* LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®
BRIEF-Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance
* Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance
BRIEF-Deerfield Management LP reports 8.28% passive stake in Lannett Co as of Oct 25, 2017-SEC filing
* Deerfield Management LP reports a 8.28 percent passive stake in Lannett Company Inc as of October 25, 2017-SEC filing Source text : ( http://bit.ly/2zi8xIn ) Further company coverage:
- Looking For Action? S&P 1500 Most Volatile Stocks
- Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results
- Lannett's (LCI) CEO Arthur Bedrosian on Q2 2018 Results - Earnings Call Transcript
- Wall Street Breakfast: Investors Calm As Government Shutdown Looms
- Your Daily Pharma Scoop: AbbVie Highlights Pipeline, Novavax Surges, Lipocine Flops At Ad Com
- Your Daily Pharma Scoop: Ultragenyx Sells Voucher, Regeneron Announces Collaboration, Madrigal Offering